Current best evidence on prescribed drugs

Pills
Drugdocs Logo

Current best evidence on prescribed drugs

Pills
HomeDrugsNewsAboutContact

DRUG ▾

ABCDEFGHIJKLMNOPQRSTUVWXYZ

DRUG

CLASS

News

Brodalumab

(Siliq®)

Brodalumab

Drug updated on 4/17/2024

Dosage FormInjection (subcutaneous: 210 mg/1.5 mL)
Drug ClassHuman interleukin-17A receptor antagonists
Ongoing and
Completed Studies		ClinicalTrials.gov

Indication

  • For the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Brodalumab (Siliq) is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.
  • A total of 22 systematic reviews and meta-analyses were reviewed, providing insights into brodalumab's effectiveness and safety profile relative to other drugs used in treating moderate-to-severe psoriasis.
  • Across multiple studies, brodalumab was consistently highlighted as one of the most effective treatments for achieving high-level outcomes such as PASI 90 and PASI 100 responses in patients with moderate-to-severe plaque psoriasis.
  • Compared against leading treatments including interleukin inhibitors (IL-17, IL-23), TNF-alpha inhibitors, PDE-4 inhibitors; brodalumab showed superior efficacy especially notable over others at reaching complete resolution of nail psoriasis by week 24-26.
  • The safety profile shows that while generally considered safe and tolerable, some concerns were raised about the risk of anti-drug antibodies development but its incidence was relatively low compared to ixekizumab; common adverse events like nasopharyngitis etc., were within expected ranges similar to other biologics targeting IL-17 pathways.
  • One analysis specifically mentioned a reduction in efficacy among ADA-positive patients treated with brodalumab which differs from observations about secukinumab where ADA presence did not significantly impact efficacy.
  • Limited data detail performance across different population subgroups however newer biologics like brodalumab show promise for broader patient populations including those who might have failed other systemic therapies; no significant differences between Asians & Caucasians noted indirectly supporting consistent performance across ethnicities.
  • Brodaluma often matched or exceeded guselkumanb’s performance when it came down achieving complete skin clearance, and showed superior effectiveness compared to older biologics like etanercept and systemic therapies like apremilast.

Product Monograph / Prescribing Information

Document TitleYearSource
Siliq (brodalumab) Prescribing Information.2020Bausch Health US, LLC, Bridgewater, NJ

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Efficacy and safety of nail psoriasis targeted therapies: a systematic review.2023American Journal of Clinical Dermatology
Anti-drug antibodies of IL-17 inhibitors for psoriasis: a systematic review. 2023The Journal of dermatological treatment.
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.2023The Cochrane database of systematic reviews.
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. 2022The Cochrane Database of Systematic Reviews
Comparison of efficacy of anti-interleukin-17 in the treatment of psoriasis between Caucasians and Asians: a systematic review and meta-analysis.2022Frontiers in Medicine
Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes.2022RMD Open
Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year. 2022Journal of Dermatological Treatment
Comparative efficacy and relative ranking of biologics and oral therapies for moderate-to-severe plaque psoriasis: a network meta-analysis 2021Dermatology and Therapy
Short-term efficacy of biologic therapies in moderate-to-severe plaque psoriasis: a systematic literature review and an enhanced multinomial network meta-analysis.2021Dermatology and Therapy
Network meta-analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method. 2021Journal of the European Academy of Dermatology and Venereology
Efficacy of a second interleukin 17 inhibitor in patients with psoriasis: a systematic review and meta-analysis. 2021Journal of the American Academy of Dermatology
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis2021The Cochrane Database of Systematic Reviews
Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis2021Journal of Dermatology Treatment
Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis. 2020Journal of the European Academy of Dermatology and Venereology
Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. 2020Journal of Dermatological Science
Efficacy of brodalumab for moderate to severe plaque psoriasis: a Canadian network meta-analysis. 2020Journal of Cutaneous Medicine and Surgery
Short-term efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: A systematic review and network meta-analysis of randomized controlled trials.2019Journal of Immunology Research
Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response.2019Journal of the European Academy of Dermatology and Venereology
Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response. 2019PLoS One
A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis. 2018The Journal of Dermatological Treatment
Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. 2018Journal of the American Academy of Dermatology
The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis. 2018The Journal of Dermatological Treatment
Brodalumab for treating moderate to severe plaque psoriasis. 2018NICE
Clinical review report: brodalumab (Siliq). 2018CADTH

Clinical Practice Guidelines

Document TitleYearSource
German S3-Guideline on the treatment of psoriasis vulgaris, adapted from EuroGuiDerm – Part 1: treatment goals and treatment recommendations. 2021Journal of the German Society of Dermatology
EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris – Part 2: specific clinical and comorbid situations.2021Journal of the European Academy of Dermatology and Venereology
EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris - Part 1: treatment and monitoring recommendations. 2020Journal of the European Academy of Dermatology and Venereology
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. 2019Journal of the American Academy of Dermatology